EQS-Adhoc

Kuros appoints Philippe Saudan as Chief Development Officer

EQS Group-Ad-hoc: Kuros Biosciences AG / Key word(s): Change of Personnel
Kuros appoints Philippe Saudan as Chief Development Officer

10.08.2016 / 07:00
Release of an ad hoc announcement pursuant to Art. 53 KR.


---------------------------------------------------------------------------

Kuros appoints Philippe Saudan as Chief Development Officer

Schlieren (Zurich), Switzerland, August 10, 2016 - Kuros Biosciences
announced today that Dr. Philippe Saudan has been appointed Chief
Development Officer and member of the Executive Board with immediate
effect. Dr. Saudan has spent the last 16 years in the pharmaceutical
industry and has held different management roles in research and
development (R&D). He has considerable experience in R&D and international
project management of multidisciplinary programs. In his last position, he
served as Chief Scientific Officer of Cytos Biotechnology, where he worked
at the interface between pre-clinical research, manufacturing and
development of several clinical projects. Since February 2016, Dr. Saudan
has been working as Head of Integration of Kuros Biosciences. In this
position, he has been closely involved in the different development
programs in tissue repair and regeneration. Dr. Saudan holds a PhD in
biology
from the University of Lausanne, Switzerland.


For further information, please contact:
Kuros Biosciences Ltd
Harry Welten, MBA
Chief Financial Officer
Tel: [phone]
[e-mail]

About Kuros Biosciences Ltd

Kuros Biosciences Ltd is focused on the development of innovative products
for tissue repair and regeneration and is located in Schlieren (Zurich),
Switzerland. The Company is listed according to the International Financial
Reporting Standard on the SIX Swiss Exchange Ltd under the symbol KURN.
Information regarding Kuros is available at www.kuros.ch.

Forward Looking Statements
This media release contains certain forward-looking statements that involve
risks and uncertainties that could cause actual results to be materially
different from historical results or from any future results expressed or
implied by such forward-looking statements. You are urged to consider
statements that include the words "will" or "expect" or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include
scientific, business, economic and financial factors, Against the
background of these uncertainties, readers should not rely on forward-
looking statements. The Company assumes no responsibility for updating
forward-looking statements or adapting them to future events or
developments.

End of ad hoc announcement
Additional features:


Document: http://n.eqs.com/c/fncls.ssp?u=AVTHLQIHUU
Document title: Kuros_CDO_160810

---------------------------------------------------------------------------

10.08.2016 News transmitted by Tensid EQS AG. www.eqs.com

---------------------------------------------------------------------------


Language: English
Company: Kuros Biosciences AG
Wagistrasse 25
8952 Schlieren
Switzerland
Phone: [phone]
Fax: [phone]
E-mail: [e-mail]
Internet: www.kuros.ch
ISIN: CH0011025217
Valor: -
Listed: Foreign Exchange(s) SIX


End of News EQS Group News Service
---------------------------------------------------------------------------

490963 10.08.2016